Praxis Precision Medicines (PRAX) recently reported fourth quarter and full year 2025 results, with net loss and loss per share from continuing operations higher than the prior year. This has put the company’s cash burn and pipeline priorities in sharper focus for investors.

The stock has been volatile, with a 1 day share price return of 2.17% and a 90 day share price return of 71.14%. The 1 year total shareholder return is very large, signalling that momentum has been strong despite recent earnings driven swings.

If this earnings update has you looking beyond a single name, it could be a good moment to broaden your search and check out 20 top founder-led companies.

With Praxis shares up strongly over the past year but still trading below the average analyst price target and some intrinsic estimates, the real question is whether you are seeing an undervalued CNS pipeline or a market already pricing in future growth.

Most Popular Narrative: 27.6% Undervalued

At a last close of $325.11 against a narrative fair value of $449.13, Praxis Precision Medicines is framed as materially undervalued by the most followed story on the stock.

Multiple late stage epilepsy programs, including vormatrigine and relutrigine with breakthrough designation in severe genetic epilepsies, create a portfolio effect in a growing CNS innovation cycle. This increases the probability of multiple approvals and a step change in total company earnings over the back half of the decade.

Want to see what kind of revenue ramp and margin shift would need to underpin that kind of earnings reset and valuation gap? The narrative leans heavily on sharp top line growth, a swing from deep losses to positive margins and a future earnings multiple that sits far above typical sector levels. Curious how those moving parts are stitched together into one fair value number?

Result: Fair Value of $449.13 (UNDERVALUED)

However, this story can change quickly if key epilepsy trials underperform or if competing treatments limit physician adoption and keep Praxis from reaching the implied earnings power.

Next Steps

With such a split narrative around Praxis, it helps to move quickly from headlines to hard facts and test the story for yourself. To see both sides set out clearly, take a look at 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If Praxis has sharpened your interest, do not stop here, your next move could be spotting an opportunity elsewhere that fits your style even better.

• Target income potential with companies that offer meaningful yields and dependable track records using our screener of 14 dividend fortresses.
• Hunt for quality trading at appealing prices by scanning our curated list of 47 high quality undervalued stocks that score well on fundamentals.
• Prioritise resilience by filtering for companies with strong finances through our solid balance sheet and fundamentals stocks screener (41 results), designed for investors who care about durability first.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.